Completed PHASE2 INTERVENTIONAL 2-arm NCT01327300

Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS) (IBS)

Randomized, Double-blind, Cross-over Study of the Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)

Sponsor: University of Florida

Conditions Irritable Bowel Syndrome

Interventions Mesalamine Placebo

Updated 6 times since 2017 Last updated: Jan 15, 2014 Started: Mar 31, 2010 Primary completion: Mar 31, 2012 Completion: Mar 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Irritable Bowel Syndrome, this trial is completed. The trial is conducted by University of Florida and has accumulated 6 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Florida

Data source: University of Florida

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gainesville, United States